06 February 2025
ANANDA PHARMA
PLC
("Ananda"
or the "Company")
Director/PDMR
Shareholding
Ananda announces that on 06 February
2025, Melissa Sturgess, the Company's Chief
Executive Officer, purchased 5,000,000 ordinary shares of 0.2p each
in the Company ("Ordinary Shares") at a price of 0.43p per Ordinary
Share.
After this transaction, Melissa
Sturgess has a beneficial interest in 427,382,284 Ordinary Shares,
representing 10.04% of the issued share capital of
Ananda.
About Ananda Pharma
Ananda Pharma (AQSE: ANA), is a
UK-based developer of licenced, cannabinoid medicines targeting the
treatment of complex, chronic conditions. The Company is led by
successful entrepreneurs and a team of world-class
scientists.
For more information, please
visit: www.anandapharma.co.uk
To stay abreast of the latest
developments at Ananda, we encourage you to follow our social media
channels which are:
·
Investor Hub: https://investors.anandapharma.co.uk/s/ea8f93
·
Instagram: https://www.instagram.com/anandapharmaplc/
·
LinkedIn:
https://www.linkedin.com/company/anandapharma
·
X:
https://twitter.com/AnandaPlc
·
Investor Meet Company:
https://www.investormeetcompany.com/ananda-pharma-plc/register-investor
-Ends-
The Directors of the Company accept
responsibility for the contents of this
announcement.
|
ANANDA PHARMA PLC
|
+44
(0)7463 686 497
|
|
|
ir@anandapharma.co.uk
|
|
Chief Executive Officer
|
|
|
Melissa Sturgess
|
|
|
|
|
|
Finance Director
|
|
|
Jeremy
Sturgess-Smith
|
|
|
|
|
|
SP
ANGEL CORPORATE FINANCE LLP
|
+44 (0)20
3470 0470
|
|
|
|
|
Corporate Finance
|
|
|
Richard Morrison
|
|
|
|
|
|
|
|
|
Corporate Broking
|
|
|
Abigail Wayne
|
|
|
Rob Rees
|
|
|
Yellow Jersey PR (media enquiries)
Sarah MacLeod
Charles Goodwin
Zara McKinlay
|
+44 (0)20
3004 9512
ananda@yellowjerseypr.com
|
Market Abuse Regulation (MAR) Disclosure
The information contained within
this announcement is deemed by the Company to constitute inside
information. Upon the publication of this announcement via a
Regulatory Information Service, this inside information is now
considered to be in the public domain.
|
Notification and public
disclosure of transactions by persons discharging managerial
responsibilities and persons closely associated with
them.
|
|
1
|
Details of the person discharging managerial responsibilities
/ person closely associated
|
|
a)
|
Name
|
Melissa Sturgess
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Chief Executive Officer
|
|
b)
|
Initial notification
/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
Ananda Pharma plc
|
|
b)
|
LEI
|
894500DFM8VOC5FW4X47
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description of the financial
instrument, type of instrument
Identification code
|
Ordinary Shares
ISIN: GB00BDQPXQ60
|
|
b)
|
Nature of the transaction
|
Purchase of Ordinary
Shares
|
|
c)
|
Price(s) and volume(s)
|
5,000,000 Ordinary Shares at 0.43p per share
|
|
d)
|
Aggregated information
- Aggregated volume
- Price
|
N/A
|
|
e)
|
Date of the transaction
|
06 February 2025
|
|
f)
|
Place of the transaction
|
Off Market
|
https://investors.anandapharma.co.uk/link/pegKZe
